Moreover, FBXO22 is highly expressed in lung adenocarcinoma patients, and promotes NSCLC cell growth via inhibiting LKB1/AMPK/mTOR signaling. This evidence concerns the gene PRKAA1 and non-small cell lung carcinoma.